On February 21, the FDA introduced that the scarcity of semaglutide injection merchandise has been resolved. Semaglutide has appeared on the FDA’s Drug Scarcity Listing since 2022 as a result of demand for the drug exceeded the obtainable provide. Initially developed and utilized for therapy of Sort 2 diabetes, semaglutide and different GLP-1 medicines can even lead to substantial weight reduction, which has made them standard for on- and off-label use by way of medicines marketed underneath model names like Ozempic and Wegovy.
Semaglutide’s presence on the Drug Scarcity Listing allowed physicians, medspas, telehealth firms, pharmacies, and outsourcing services higher latitude to make compounded variations of the remedy obtainable to their sufferers to satisfy the elevated demand at a a lot decrease price than the favored model title variations. Well being care suppliers who’ve supplied compounded variations of semaglutide for weight reduction and weight administration will now be severely restricted in how they’re permitted to compound these medicines for his or her sufferers.
The FDA will chorus from appearing in opposition to compounders for violations of the federal Meals, Drug & Beauty Act (“FD&C Act”) arising from situations that depend on semaglutide’s inclusion on the Drug Scarcity Listing as a way to keep away from pointless disruptions to affected person therapy, however solely till the next dates:
- For state-licensed pharmacies or physicians compounding underneath Part 503A of the FD&C Act: compounding, distributing, or shelling out semaglutide injection merchandise which can be “basically a replica” of an FDA-approved product: till April 22, 2025.
- For outsourcing services underneath Part 503B of the FD&C Act: compounding, distributing, or shelling out semaglutide injection merchandise which can be “basically a replica” of an FDA-approved product: till Could 22, 2025.
The FDA should take enforcement actions throughout this time relating to different statutory or regulatory violations, equivalent to these referring to product high quality or security.
This motion by the FDA creates a sea change in how well being care suppliers who prescribe or compound semaglutide injection merchandise might be permitted to prescribe and compound these medicines going ahead. Now not will medical practices and medspas be capable of financially profit from prescribing, compounding, and shelling out compounded semaglutide merchandise which can be “basically copies” of their model title counterparts. Sufferers can even need to pay for the price of model title semaglutide merchandise in the event that they proceed therapy.
For related causes, this modification can even have a considerable affect on pharmacies, outsourcing services, and telehealth firms specializing in compounded semaglutide injection merchandise.
In case your well being care follow, medspa, or enterprise engages in prescribing or compounding semaglutide injection merchandise, consulting with skilled well being care attorneys properly upfront of the shortly approaching deadlines can assist keep away from important compliance dangers.
In case you have any questions relating to how this modification will have an effect on your enterprise, please contact Jonathan B. Schall (jschall@foxrothschild.com) and Edward J. Cyran (ecyran@foxrothschild.com).